Aims

As part of the SURE programme, SURE Denmark/Sweden aimed to study the real-world use of once-weekly (OW) semaglutide in adults with type 2 diabetes (T2D) in Denmark/Sweden.

Methods

SURE Denmark/Sweden was an ∼30-week, prospective, multicentre, open-label, observational study, enrolling adults with T2D and ≥1 documented HbA_1c value ≤12 weeks before initiating semaglutide at their physician’s discretion. Primary (change in HbA_1c) and secondary (including change in body weight, glycaemic and weight-loss target achievement) endpoints were assessed between baseline and end of study (EOS).

Results

Of the 331 patients initiating semaglutide, 282 (85%) completed the study on treatment. For the latter, estimated mean changes [95% confidence interval] in HbA_1c and body weight between baseline and EOS were –1.2 [–1.3; –1.1]%-points (–13 [–14; –12] mmol/mol) and –5.4 [–6.0; –4.7] kg (both p < 0.0001), respectively, with similar results in Denmark and Sweden. At EOS, 67.5% of patients achieved HbA_1c <7%; 49.4% achieved a weight reduction of ≥5%. Reported adverse events were consistent with the known safety profile of semaglutide.

Conclusions

In routine clinical practice in Denmark/Sweden, use of OW semaglutide was associated with glycaemic and weight-loss benefits in a wide range of adults with T2D, supporting real-world use.

ClinicalTrials.gov Identifier

NCT03648281.

中文翻译：

---

每周一次索马鲁肽在 2 型糖尿病患者中的实际应用：SURE 丹麦/瑞典多中心、前瞻性、观察性研究的结果

目标

作为 SURE 计划的一部分，SURE 丹麦/瑞典旨在研究丹麦/瑞典成人 2 型糖尿病 (T2D) 成人每周一次 (OW) semaglutide 的实际使用情况。

方法

SURE Denmark/Sweden 是一项为期 30 周、前瞻性、多中心、开放标签的观察性研究，招募了患有 T2D 且有 ≥1 个记录的 HbA _1c值≤12 周的 T2D 成年人，由医生自行决定开始使用 semaglutide。在基线和研究结束 (EOS) 之间评估主要（HbA _1c的变化）和次要（包括体重、血糖和减肥目标实现的变化）终点。

结果

在开始使用 semaglutide 的 331 名患者中，282 名 (85%) 完成了治疗研究。对于后者，基线和 EOS 之间 HbA _1c和体重的估计平均变化 [95% 置信区间] 为 –1.2 [–1.3；–1.1]% 点 (–13 [–14; –12] mmol/mol) 和 –5.4 [–6.0; –4.7] kg（均 p < 0.0001），丹麦和瑞典的结果相似。在 EOS，67.5% 的患者 HbA _1c <7%；49.4% 实现了 ≥5% 的减重。报告的不良事件与已知的索马鲁肽安全性特征一致。

结论

在丹麦/瑞典的常规临床实践中，OW semaglutide 的使用与广泛的 T2D 成年人的血糖和体重减轻相关，支持现实世界的使用。

ClinicalTrials.gov 标识符

NCT03648281。